Proudly sponsored by

J&J shot study shows Covid infections halved in health workers

Like all Covid vaccines, J&J’s was intended and tested for its ability to prevent Covid hospitalisations and deaths.
Image: Mario Tama/Getty Images North America

Johnson & Johnson’s Covid-19 vaccine cuts the risk of getting infected with the disease by about half, according to the latest results of a trial involving almost half a million health workers in South Africa.

The vast majority of the breakthrough infections were mild, Glenda Gray, co-leader of the study known as Sisonke, said in an interview, citing unpublished data from the trial, which had earlier shown the shot’s effectiveness against severe illness.

Moneyweb Insider INSIDERGOLD

Subscribe for full access to all our share and unit trust data tools, our award-winning articles, and support quality journalism in the process.

Choose an option:

R63 per month
R630 per year SAVE R126

You will be redirected to a checkout page.
To view all features and options, click here.

A monthly subscription is charged pro rata, based on the day of purchase. This is non-refundable and includes a R5 once-off sign-up fee.
A yearly subscription is refundable within 14 days of purchase and includes a 365-day membership.

Click here for more information.

Like all Covid vaccines, J&J’s was intended and tested for its ability to prevent Covid hospitalisations and deaths. Even so, the frequency of breakthrough infections in vaccinated people highlights the challenge governments face in halting the virus’s spread, which threatens to lead to the proliferation of new variants that may be even more contagious.

Coupled with vaccine hesitancy, the limited efficacy of shots in stopping mild infections will mean “we will continue to see a flow of infections,” said Bruce Mellado, a professor at the University of the Witwatersrand in Johannesburg who uses modeling to predict the trajectory of infections. Still, he said, the effectiveness against death and severe disease could prevent a “human catastrophe.”

J&J didn’t immediately respond to a request for comment.

The study included several weeks during which South Africa was going through a third wave of coronavirus infections, spurred by the highly contagious delta variant. The emergence of new, fast-spreading strains has made earlier goals of herd immunity — when the proportion of the population that’s vulnerable to the virus sinks so low that it stifles spread — harder to reach.

By cutting the number and the intensity of infections, the vaccines limit the chance of further mutated strains emerging. Yet for many countries, the focus has shifted to reducing the seriousness of illness and subsequent demand for more intensive treatments.

‘Not unique’

The Sisonke trial measured breakthrough infections both by asking participants to report a positive result as well as by getting daily alerts from testing laboratories. The researchers also tapped data systems to see who had been hospitalised or died.

Initial results from Sisonke, released August 6, showed J&J’s single-dose vaccine was about 70% effective against hospitalization and as much as 96% effective against death. The trial didn’t include the use of a placebo. The final results which include three sets of data from private insurers and the government, will be submitted for publication in days, said Gray, who’s a research professor at the University of the Witwatersrand.

The J&J vaccine, a key element in South Africa’s vaccination plan, has also been given to teachers, police, and other government employees. It’s expected to play an important role in reaching remote areas, as it can be stored at refrigerator temperature.

The Sisonke trial was put in place in February after the South African government’s plans to use AstraZeneca Plc’s shot showed limited efficacy against mild cases, disrupting government plans for a wide government rollout. Gray and other scientists concluded an agreement with J&J to run a mass trial.

Other vaccines in wide use have indicated vulnerability to breakthrough infections. A study released August 9 showed that Moderna Inc.’s was associated with a two-fold reduction of breakthrough risk compared with the shot from Pfizer Inc. and BioNTech SE. The results were reported ahead of peer review.

The results against breakthrough infections are “not unique to Johnson & Johnson, but also for other vaccines,” said Shabir Madhi, a vaccinologist from the University of the Witwatersrand who led trials of both AstraZeneca’s and Novavax Inc.’s shots in South Africa. “It comes as little surprise with ongoing evolution of the virus.”

© 2021 Bloomberg

COMMENTS   4

Sort by:
  • Oldest first
  • Newest first
  • Top voted

You must be signed in to comment.

SIGN IN SIGN UP

If this covid business is really as bad as the March 2020 proposals halve of the worlds population would by now have been dead. I found that good old remedies like ginger, brandy combined with keeping warm and a healthy lifestyle kept me from getting this nasty virus ever since March 2020. So why would I have someone inject me with nasty stuff that gives me a 50-50 chance of not getting this infection.

Did you read the article? The very first line “Like all Covid vaccines, J&J’s was intended and tested for its ability to prevent Covid hospitalisations and deaths.”
On Monday at Groote Schuur there were 153 unvaccinated and 3 vaccinated patients. 66 unvaccinated and 0 vaccinated in high care. 32 unvaccinated and 0 vaccinated on ventilators.
Covid vaccines are not about stopping you getting it, but stopping you getting hospitalised, and lowering the chance of you spreading it.

The Groote Schuur meme going around is a hoax. It’s been going around with different hospital logos.

Any safe data that comes out at this stage is short term and irrelevant. The concern is the long term safety data, which doesn’t exist and cannot exist until at least the next 3 years. Probably longer than that.

End of comments.

LATEST CURRENCIES  

USD / ZAR
GBP / ZAR
EUR / ZAR
BTC / USD

Podcasts

INSIDER SUBSCRIPTIONS APP VIDEOS RADIO / LISTEN LIVE SHOP OFFERS WEBINARS NEWSLETTERS TRENDING PORTFOLIO TOOL CPD HUB

Follow us:

Search Articles:
Click a Company: